Cargando…
Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype
BACKGROUND: Adverse drug reactions (ADRs) are frequent occurring events that can essentially be defined as harmful or unpleasant symptoms secondary to the use of a medicinal product. ADRs involve a wide spectrum of clinical manifestations ranging from minor itching and rash to life-threatening react...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935440/ https://www.ncbi.nlm.nih.gov/pubmed/33688237 http://dx.doi.org/10.2147/PGPM.S289869 |
_version_ | 1783661001554526208 |
---|---|
author | Fonseca, Dora Janeth Morel, Adrien Llinás-Caballero, Kevin Bolívar-Salazar, David Laissue, Paul |
author_facet | Fonseca, Dora Janeth Morel, Adrien Llinás-Caballero, Kevin Bolívar-Salazar, David Laissue, Paul |
author_sort | Fonseca, Dora Janeth |
collection | PubMed |
description | BACKGROUND: Adverse drug reactions (ADRs) are frequent occurring events that can essentially be defined as harmful or unpleasant symptoms secondary to the use of a medicinal product. ADRs involve a wide spectrum of clinical manifestations ranging from minor itching and rash to life-threatening reactions. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare ADRs. SJS-TEN may be considered a polygenic pathology due to additive/epistatic effects caused by sequence variants in numerous genes. Next-generation sequencing (NGS) represents a potentially interesting exploration tool in such scenario as it facilitates the simultaneous analysis of large genomic regions and genes at affordable cost. METHODS: The present study has involved using whole-exome sequencing (WES) for the first time on SJS-TEN patients. It involved robust and innovative multistep bioinformatics analysis focusing on 313 candidate genes potentially participating in the disease’s aetiology, specific drugs’ metabolism and gene regulation. RESULTS: We identified combinations of frequently occurring and rare variants that may contribute to the disease’s pathogenesis. Depending on the specific drug being taken, different variants (and alleles) in NAT2, CYP2D8, CYP2B6, ABCC2, UGT2B7 and TCF3 were identified as coherent candidates representing potential future markers for SJS-TEN. CONCLUSION: The present study proposed and has described (for the first time) a large-scale genomic analysis of patients affected by SJS-TEN. The genes and variants identified represent relevant candidates potentially participating in the disease’s pathogenesis. Corroborating that proposed by others, we found that complex combinations of frequently occurring and rare variants participating in particular drug metabolism molecular cascades could be associated with the phenotype. TCF3 TF may be considered a coherent candidate for SJS-TEN that should be analysed in new cohorts of patients having ADRs. |
format | Online Article Text |
id | pubmed-7935440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-79354402021-03-08 Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype Fonseca, Dora Janeth Morel, Adrien Llinás-Caballero, Kevin Bolívar-Salazar, David Laissue, Paul Pharmgenomics Pers Med Original Research BACKGROUND: Adverse drug reactions (ADRs) are frequent occurring events that can essentially be defined as harmful or unpleasant symptoms secondary to the use of a medicinal product. ADRs involve a wide spectrum of clinical manifestations ranging from minor itching and rash to life-threatening reactions. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare ADRs. SJS-TEN may be considered a polygenic pathology due to additive/epistatic effects caused by sequence variants in numerous genes. Next-generation sequencing (NGS) represents a potentially interesting exploration tool in such scenario as it facilitates the simultaneous analysis of large genomic regions and genes at affordable cost. METHODS: The present study has involved using whole-exome sequencing (WES) for the first time on SJS-TEN patients. It involved robust and innovative multistep bioinformatics analysis focusing on 313 candidate genes potentially participating in the disease’s aetiology, specific drugs’ metabolism and gene regulation. RESULTS: We identified combinations of frequently occurring and rare variants that may contribute to the disease’s pathogenesis. Depending on the specific drug being taken, different variants (and alleles) in NAT2, CYP2D8, CYP2B6, ABCC2, UGT2B7 and TCF3 were identified as coherent candidates representing potential future markers for SJS-TEN. CONCLUSION: The present study proposed and has described (for the first time) a large-scale genomic analysis of patients affected by SJS-TEN. The genes and variants identified represent relevant candidates potentially participating in the disease’s pathogenesis. Corroborating that proposed by others, we found that complex combinations of frequently occurring and rare variants participating in particular drug metabolism molecular cascades could be associated with the phenotype. TCF3 TF may be considered a coherent candidate for SJS-TEN that should be analysed in new cohorts of patients having ADRs. Dove 2021-03-01 /pmc/articles/PMC7935440/ /pubmed/33688237 http://dx.doi.org/10.2147/PGPM.S289869 Text en © 2021 Fonseca et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Fonseca, Dora Janeth Morel, Adrien Llinás-Caballero, Kevin Bolívar-Salazar, David Laissue, Paul Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype |
title | Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype |
title_full | Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype |
title_fullStr | Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype |
title_full_unstemmed | Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype |
title_short | Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype |
title_sort | whole-exome sequencing in patients affected by stevens-johnson syndrome and toxic epidermal necrolysis reveals new variants potentially contributing to the phenotype |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935440/ https://www.ncbi.nlm.nih.gov/pubmed/33688237 http://dx.doi.org/10.2147/PGPM.S289869 |
work_keys_str_mv | AT fonsecadorajaneth wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype AT moreladrien wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype AT llinascaballerokevin wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype AT bolivarsalazardavid wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype AT laissuepaul wholeexomesequencinginpatientsaffectedbystevensjohnsonsyndromeandtoxicepidermalnecrolysisrevealsnewvariantspotentiallycontributingtothephenotype |